EurekaMag.com logo
+ Translate

Electrophysiological effects of encainide and its metabolites in 11 patients


, : Electrophysiological effects of encainide and its metabolites in 11 patients. Journal of Cardiovascular Pharmacology 7(6): 1077-1082

Encainide is a new antiarrhythmic class IC agent. Eleven patients were given 1 mg/kg of encainide i.v. over a 15-min period. Electrophysiological studies were done before and l h after drug administration. Blood levels of encainide and its principle metabolites O-demethyl-encainide, 3 metoxy-O-demetyl-encainide and N-demethyl-encainide were measured serially after drug administration. Heart rate, blood pressure, and conduction intervals were monitored. Sixty minutes after drug administration there was a marked increase of the QRS, PA, AH, and HV intervals of 28.1% (p less than 0.01), 17.2% (p less than 0.01), 22.4% (p less than 0.01), and 32.2% (p less than 0.01), respectively, and a slight increase of the Wenckebach cycle length of 8% (p less than 0.05). BP, RR, QT, CSNRT, ESACT, ERP, and FRP did not vary significantly. The HV interval already was increased significantly 2 min after drug administration, while AH was not increased until 15 min after drug administration. The average blood levels of encainide and ODE 60 min after drug administration were 0.410 +/- 0.12 and 0.176 +/- 0.09 microgram/ml, respectively (mean +/- SE of the mean). There was a positive correlation between the increase of the AH and the blood level of ODE, which points out the importance of prolonged electrophysiological studies when testing drug with possibly active metabolites.

(PDF same-day service: $19.90)

Accession: 005349566

PMID: 2418291

DOI: 10.1097/00005344-198511000-00010

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Kerr, M.J.; Allen, J.D.; Harron, D.W.; Shanks, R.G., 1985: The effects of encainide and its major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, on experimental cardiac arrhythmias in dogs. Encainide (E) is a class I antiarrhythmic agent which is metabolised in humans, with the formation in the majority of patients of O-demethyl encainide (ODE) and 3-methoxy-O-demethyl encainide (MODE). As it has been suggested that these metabolites...

Barbey, J.T.; Thompson, K.A.; Echt, D.S.; Woosley, R.L.; Roden, D.M., 1988: Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. Although encainide is an effective antiarrhythmic agent, plasma concentrations and pharmacologic effects are not well correlated. One explanation is the generation of active metabolites: while in most patients (extensive metabolizers; EMs) concent...

Barbey J.T.; Thompson K.A.; Echt D.S.; Woosley R.L.; Roden D.M., 1988: Antiarrhythmic activity electrocardiographic effects and pharmacokinetics of the encainide metabolites o demethylencainide and 3 methoxy o desmethyl encainide in man. Although encainide is an effective antiarrhythmic agent, plasma concentrations and pharmacologic effects are not well correlated. One explanation is the generation of active metabolites: while in most patients (extensive metabolizers; EMs) concent...

Chimienti, M.; Salerno, J.A.; Moizi, M.; Klersy, C.; Marangoni, E.; Previtali, M.; Bianchi, P.E.; Montemartini, C.; Bobba, P., 1985: Intravenous and oral encainide: electrophysiological effects in patients with paroxysmal reciprocating supraventricular tachycardia. The electrophysiologic effects of encainide (E) after acute i.v. (1 mg/kg in 60') and oral administration (75 to 150 mg/die for 48-72 h) were evaluated in 10 pts with PSVT (5 men and 5 women, mean age 48 +/- 15 years). The mechanism of PSVT w...

Kinnaird, A.A.; Man, R.Y., 1989: Electrophysiological effects of encainide and its metabolites in normal canine Purkinje fibers and Purkinje fibers surviving infarction. In this study, we assessed the effects of O-demethyl encainide (0.5 .mu.M), the most active metabolite of encainide, and the combination with 3-methoxy-O-demethyl encainide (0.5 .mu.M) and encainide (0.1 .mu.M) on cardiac action potential characte...

Latini, R.; Gillis, A.M.; Kates, R.E., 1984: Myocardial uptake of encainide and its two major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, in the dog. Encainide is a new antiarrhythmic agent which is currently undergoing clinical evaluation. Two metabolites, O-demethyl encainide (ODE) and 3-methoxy-O-demethyl encainide (MODE), have been identified. We have investigated the myocardial accumulatio...

Latini R.; Gillis A.M.; Kates R.E., 1984: Myo cardial uptake of encainide and its 2 major metabolites o demethyl encainide and 3 methoxy o demethyl encainide in the dog. Encainide is a new antiarrhythmic agent which is currently undergoing clinical evaluation. Two metabolites, O-demethyl encainide (ODE) and 3-methoxy-O-demethyl encainide (MODE), were identified. The myocardial accumulation of these 3 compounds in...

Winkle, R.A.; Peters, F.; Kates, R.E.; Harrison, D.C., 1983: Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide. To establish long-term efficacy and the relation between drug plasma concentration and antiarrhythmic response, 12 patients with encainide-responsive frequent complex ventricular ectopic activity underwent 1 year of therapy with encainide. Twenty-...

Harrison D.C., 1983: Increased incidence of heart block induced by combined encainide encainide metabolites and verapamil in dogs. American Heart Association Monograph: Iii-270

Cassagneau, B.; Calazel, J.; Puel, J.; Massabuau, P.; Miquel, J.P.; Bounhoure, J.P.; Marin, T.; Narula, O.S., 1984: Electrophysiological effects of encainide in man. Encainide is an antiarrhythmic agent under evaluation; it is effective in ventricular and supraventricular arrhythmias. Its electrophysiological effects seem to differ according to the route of administration, oral or intravenous, probably because...